Document is current
Any future updates will be listed below
-
Authors
Wu, Qiu Jing
Tymianski, Michael
-
Funding
Funding for this research was provided by:
Canada Research Chairs program
- License Information
-
More Information
Article History
Received: 15 January 2018
Accepted: 1 March 2018
First Online: 13 March 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Dr. Michael Tymianski is M.T. is a Canada Research Chair (Tier 1) in Translational Stroke Research, and the CEO of NoNO Inc., a biotechnology company developing NA-1 for clinical use. QJW has no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
